PPARG and colorectal carcinoma: Studies have reported that administration of PPARG ligands (pioglitazone, troglitazone) in colorectal carcinoma cells enhances the expression of the Bax protein and thus enhances the apoptosis while simultaneously diminishing the expression of Bcl-2, a gene inhibiting programmed cell death [10].